Posted in | News | Nanoanalysis | Nanofluidics

Fluidigm Unveils New Nanofluidic Technology-Based Genome Analysis System

Fluidigm today introduced the new BioMark™ HD Real-time PCR System, the company’s most advanced instrument for genomic analysis ever.

The BioMark HD System is designed for researchers who require the sensitivity and throughput needed to study gene expression down to the single-cell level -- especially those who have limited amounts of sample or study rare populations of cells.

The BioMark HD System is the newest member of the BioMark family, which has delivered significant scientific insights to over 200 customers around the world. In addition to the sizeable throughput advances, the new BioMark HD System features a number of other important design changes incorporated to improve performance, lower operating costs and provide an expanded applications suite.

“We expect our customers to embrace the improved capabilities of the new BioMark HD platform, as it is designed to provide them with even greater efficiencies,” said Gajus Worthington, president and chief executive officer of Fluidigm. “The BioMark HD System is designed to provide exceptional data quality, extraordinary flexibility, and faster time-to-results that collectively allow researchers to analyze their experimental outcomes rapidly and publish their results sooner.”

The BioMark HD System relies on the same Fluidigm nanofluidic technology that delivers savings in cost and time by providing massive parallelism of experiments and an easy-to-use workflow. By incorporating a new fast thermal cycling protocol, the BioMark HD System reduces time-to-result by increasing the throughput of the original system two-fold. Users now have the ability to generate over 50,000 data points in one day with only one technician. The fast thermal cycling protocol is compatible with commercially available assays and yields data that is equal in quality to standard cycling protocol data.

The BioMark HD platform continues to support all the applications of the original BioMark System, including gene expression, single-cell gene expression, and genotyping. Using Digital Array chips, the BioMark HD System performs common digital PCR applications, such as mutation detection, copy number variation, and absolute quantitation of nucleic acid sequences.

The BioMark HD System is now available for purchase from Fluidigm and its licensed distributors throughout the world.

Source: http://www.fluidigm.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Standard BioTools. (2019, February 12). Fluidigm Unveils New Nanofluidic Technology-Based Genome Analysis System. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=21441.

  • MLA

    Standard BioTools. "Fluidigm Unveils New Nanofluidic Technology-Based Genome Analysis System". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=21441>.

  • Chicago

    Standard BioTools. "Fluidigm Unveils New Nanofluidic Technology-Based Genome Analysis System". AZoNano. https://www.azonano.com/news.aspx?newsID=21441. (accessed November 21, 2024).

  • Harvard

    Standard BioTools. 2019. Fluidigm Unveils New Nanofluidic Technology-Based Genome Analysis System. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=21441.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.